Are you offering focal radiation dose escalation (microboost) to gross intraprostatic disease for patients with intermediate or high risk prostate cancer?
This new #advancesRO article from Regan et al was presented at #ASTRO24's Poster Q&A Session 08. Read their article "Microboost in Localized Prostate Cancer: Analysis of a Statewide Quality Consortium" here: https://t.co/w8TBySdXqw
Our chief resident @SamReganMD taking the stage at #ASTRO24 to discuss @UMichRadOnc head and neck group's work exploring ctDNA in HPV+ head and neck cancer.
“We plan to continue to investigate the role of multimodal approaches for de-escalation of therapy for this patient population,” said Samuel Regan, MD. #hncsm#HNCS24 | @ASTRO_org@SamReganMD
https://t.co/l1iYpF1H5W
Our HNCa rad onc team's innovative work demonstrates enhanced patient quality of life with reduced chemo radiation in HPV+ oropharynx ca, all while ensuring tumor control!
Kudos to @MierzwaMichelle@SamReganMD and team!
@UMRogelCancer@umichmedicine
https://t.co/uRkANyggiT
Congrats to two of our residents, Michael Dykstra and Sam Regan, for winning Conquer Cancer Merit Awards for their ASCO GU symposium abstracts! Both will be presenting work done with @MROQC1.
https://t.co/Q6WUHmWWfM
@mdsquared44@SamReganMD@UMichRadOnc @UMichMedSchool
Happy Halloween from University of Michigan Department of Radiation Oncology! The most caring animals you will find anywhere. 👻🎃🎃👻
Wishing everyone a safe Halloween!
@UMRogelCancer@umichmedicine@ASTRO_org@ASCO
Delighted to present updated data from the PACIFIC trial in unresectable Stage III NSCLC @myESMO
Durable benefit with durvalumab @4 years
- almost 50% of patients alive
- MS reached for the first time and is an unprecedented 47.5 months
=major benefit for patients @MCRCnews